Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2016- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival -
NEWTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical data describing XPO1...
-
Sep 28, 2016- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models-
NEWTON, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical and Phase 1 clinical data...
-
Sep 12, 2016
NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD,...
-
Sep 6, 2016- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease -
NEWTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from its Phase 2b...
-
Aug 30, 2016
NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line...
-
Aug 4, 2016Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma
NEWTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2016...
-
Aug 3, 2016
NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Jul 28, 2016
NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016...
-
Jul 27, 2016Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose
NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that data from its Phase 1b clinical trial...
-
Jul 27, 2016- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers -
NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts have been selected for...
-
Jul 6, 2016
NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
-
Jun 22, 2016
NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1...
-
Jun 16, 2016- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -
NEWTON, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today provided an update relating to certain clinical...
-
Jun 15, 2016
NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
-
Jun 10, 2016- Preclinical Data for Second-Generation SINE™ Compound, KPT-8602, Also Featured -
NEWTON, Mass., June 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced a poster presentation highlighting updated...
-
Jun 1, 2016
NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer...
-
May 19, 2016
NEWTON, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary...
-
May 18, 2016
NEWTON, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor...
-
May 9, 2016Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
NEWTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2016 and...
-
May 2, 2016
NEWTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016...
-
Apr 20, 2016
NEWTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity...
-
Apr 5, 2016
NEWTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
-
Mar 31, 2016
NEWTON, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the...
-
Mar 16, 2016Two Late-Breaking Posters Featuring the Company's Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602
NEWTON, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 19 abstracts describing the Company's...
-
Mar 14, 2016Company Continues to Expand its Leadership in SINETM-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs
NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and...